Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Fludarabine + ROR1 CAR-T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 15||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|ROR1 CAR-T cells||autologous ROR1-CAR-T cells||ROR1 CAR-T cells are autologous T-lymphocytes engineered to express anti-ROR1 single-chain variable fragment linked to CD28 transmembrane domain, and either 4-1BB/CD3zeta or CD28/CD3zeta signaling domains, which potentially induces immune response against ROR1-expressing tumor cells, leading to apoptosis and tumor cell lysis (PMID: 31415244).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02706392||Phase I||Cyclophosphamide + Fludarabine + ROR1 CAR-T cells||Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies||Recruiting||USA||0|